Because TP53 mutation associated with accumulation of p53 protein represents one of the widespread gene alterations in the HPV (-) HNSCCs, targeting WT or mutant p53 via tumor vaccine has been a primary approach tested in clinical trials. The gene discussed is TP53; the disease is neoplasm.